Exir Bio

Exir Bio is an emerging entity in the biomedical sector that employs stem cells and primary cells derived from non-human primates for conducting in vitro evaluations of drug efficacy and safety. The platform significantly reduces, refines, and replaces the utilization of non-human primates in biomedical studies, accelerating the pace of preclinical safety evaluations. This is in line with FDA Modernization Act 2.0 and advancement of New Approach Methods (NAMs) for drug efficacy and safety assessments. We have pioneered proprietary technology that harnesses primate stem cells, paving the way for enhanced drug screening, gene manipulation, and cell therapy. By adopting the in vitro approach, Exir Bio successfully eliminates the need for live monkeys in biomedical investigations. This leads to a considerable reduction in time and expenses for early drug discovery, efficacy, and safety screening. In addition to being a more time and cost-effective method, it also promotes a more humane approach to biomedical research.